timothy sykes logo
MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer And Telehealth Thumbnail
G Google News

MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer And Telehealth

BRYCE TUOHEY•UPDATED SEP. 28, 2026, 7:47 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

DataMeds AI Inc. stocks have been trading up by 23.79 percent after unveiling a breakthrough healthcare diagnostics AI platform.

Key Takeaways

  • DataMEDS AI completed the $1.5M Helomics acquisition and received $1.5M in cash while avoiding legacy third-party debt, expanding from chronic conditions into AI-driven oncology diagnostics.
  • Following the Helomics deal, MEDS shares spiked roughly 305% on huge trading volume, signaling intense momentum and speculative interest around the new cancer-focused strategy.
  • DataMeds AI settled Wellgistics-related litigation, wiping out about $19M in liabilities and retiring 364,099 shares for a $450,000 cash payment, simplifying its capital structure.
  • Through the “Health Lives Here” campaign with Tollo Health and the NFL Alumni Association, MEDS is pushing a national telehealth and pharmacy app anchored by its EinsteinRx AI and PharmacyChain blockchain.
  • DataMEDS AI launched an AI-focused corporate site, is preparing a soft launch of its Health Lives Here consumer app, and will showcase its tech at the 2026 National Telehealth and Virtual Care Summit.

Candlestick Chart

Live Update At 07:47:28 EDT: On Monday, September 28, 2026 DataMeds AI Inc. stock [NASDAQ: MEDS] is trending up by 23.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MEDS has been trading like a textbook low-float momentum play. In early September 2026, DataMeds AI Inc. sat under $1, grinding between roughly $0.85 and $0.97. Then the Helomics news hit. On 2026/09/15, MEDS ripped from a $0.89 open to close at $1.62. The real fireworks came on 2026/09/16, when the stock exploded intraday to $12.31 and closed at $6.07, more than a 300% surge on extraordinary volume.

Since then, the chart shows a steady fade. By 2026/09/25, MEDS closed near $3.11 after a series of lower highs from $6.73 down into the low $3s. Intraday data on the latest session shows heavy range trading between about $3 and $4.9, classic action for a former runner where day traders are scalping volatility while longer-term players reassess.

More Breaking News

Under the hood, the fundamentals are still rough. MEDS generated about $23.3M in revenue over the trailing period, but profit margins are deeply negative and the company posted roughly -$18.4M in net income for the latest reported quarter. Cash at period-end was just $2.46M against current liabilities of about $39.4M, with a current ratio around 0.1 — a clear sign of balance-sheet stress. For traders, that mix — massive recent run, weak but improving capital structure, and big story catalysts — screams “trading vehicle,” not stable blue chip.

Why Traders Are Watching MEDS Now

The heart of the story is the Helomics acquisition. DataMEDS AI paid $1.5M in stock and notes for an AI-driven cancer diagnostics and predictive oncology CRO business and, crucially, received $1.5M in cash back as part of the transaction. MEDS also picked up a CLIA/CAP‑certified clinical lab, equipment, and a contract research central lab business — and did it without taking on third‑party debt or legacy payables beyond normal operating costs. For a tiny, cash-strained name, that’s a capital-light way to step into higher-value oncology.

Traders latched onto that instantly. When MEDS finalized the Helomics deal, the stock ripped more than 300% in a single session. That kind of move tells you where sentiment flipped: the market started to treat DataMEDS AI less like a struggling chronic-condition platform and more like an emerging AI‑oncology and health IT play.

Helomics also fits the broader MEDS tech stack. Management plans to expand into cancer screening, molecular profiling, traditional CLIA lab services, and nutritional support for cancer patients. Tie that to the company’s EinsteinRx AI engine and PharmacyChain blockchain, and MEDS is trying to brand itself as a data-driven healthcare network, not just another telehealth middleman.

At the same time, DataMeds AI is cleaning up its past. Settling the Wellgistics dispute erased about $19M in liabilities and retired 364,099 shares for only $450,000 in cash. That is a huge liability reduction relative to the outlay and takes a big overhang off the table — exactly the kind of balance-sheet move momentum traders love to see when a story is turning.

Add the “Health Lives Here” campaign with Tollo Health and the NFL Alumni Association, plus a new AI-focused corporate website and plans to present at the 2026 National Telehealth and Virtual Care Summit, and MEDS now has a full narrative arc: oncology data, national telehealth reach, AI branding, and pending expansion deals with groups like DataVault AI.

Conclusion

For active traders, MEDS is a classic high-risk, high-reward story. On one hand, the fundamentals show heavy losses, negative equity, and a tight liquidity position. DataMeds AI Inc. ended the last reported quarter with about $2.46M in cash versus more than $39M in current liabilities, and margins remain deeply in the red. Those numbers remind everyone this is still a turnaround, not a finished product.

On the other hand, the company has stacked a surprising number of bullish corporate actions in a short window. The Helomics acquisition handed MEDS a CLIA/CAP-certified AI cancer diagnostics platform plus $1.5M in cash. The Wellgistics settlement removed roughly $19M in liabilities and cleaned up the share count. The Health Lives Here push, powered by EinsteinRx AI and PharmacyChain, gives DataMEDS AI a visible consumer channel and national narrative. The upcoming National Telehealth and Virtual Care Summit appearance keeps potential catalysts on the calendar.

For traders who study charts and catalysts, MEDS now sits in that volatile middle ground between hype and execution. The parabolic run off the Helomics news has cooled, but the story is still live. As Tim Sykes likes to say, “Volatility is opportunity, but only for prepared traders.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”. MEDS is offering plenty of volatility; the challenge now is treating it as a trading setup, not a guarantee, and always respecting risk in a name this speculative.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”